On August 19, 2026, the pharmaceutical world was set ablaze. US drug giants Moderna and Merck jointly announced the successful Phase III INTerpath-001 clinical trial of their personalized mRNA neoantigen cancer vaccine (mRNA-4157/V940) for melanoma treatment. The news sent Moderna shares soaring an unprecedented 176.97% in a single day, while partner Merck hit an all-time high. By August 20, A-share and Hong Kong-listed pharmaceutical stocks exploded across the board, with related ETFs such as Medical ETF Huabao (512170) and HK Connect Innovative Drug ETF Huabao (520880) all surging.

What exactly is this vaccine, why has it instantly ignited capital markets, and where do the investment opportunities lie? Let's dive in.

Unlike preventive mRNA vaccines (such as COVID-19 shots) used in healthy populations, mRNA-4157/V940 is a therapeutic tumor mRNA vaccine designed for postoperative adjuvant treatment in melanoma patients to prevent cancer recurrence. How does it work? The mRNA vaccine tags tumor cells, training T cells to recognize and kill them while generating sustained immune responses that suppress recurrence. When combined with Keytruda (a PD-1 antibody), it releases the immune brakes, achieving a synergistic "1+1>2" anti-cancer effect.

In simple terms, this is a one-person, one-vaccine approach—a bespoke vaccine crafted for each cancer patient, teaching their immune system to precisely hunt down cancer cells. The process involves sequencing the patient's tumor tissue, using AI algorithms to identify unique cancer "fingerprints" (neoantigens), encoding up to 34 of these features into mRNA, and injecting the customized vaccine to train the immune system to attack residual cancer cells. If traditional chemotherapy is "indiscriminate bombing" and targeted drugs are "precision strikes on one target that often lead to resistance," this vaccine essentially hands the immune system a "wanted poster" for cancer cells—eliminate anything that looks like this.

Why is this so significant? mRNA-4157/V940 is the first personalized mRNA cancer therapy in human history to prove efficacy in a Phase III trial. It overturns the traditional "drug-finds-patient" paradigm, validating a new logic of "precision manhunt" in oncology and proving that the path of personalized cancer vaccines is viable.

First, mRNA technology has crossed from "prevention" into "treatment." Previously, the most successful mRNA application was COVID vaccines—preventing healthy people from getting sick. Now, it's therapeutic—treating those already diagnosed with cancer. The vaccine industry's ceiling has vaulted from a tens-of-billions infectious disease prevention market to a hundreds-of-billions oncology treatment market.

Second, "one person, one drug" has gone from science fiction to reality. The old pharmaceutical logic was "one drug treats many." The mRNA cancer vaccine logic is "one person, one medicine"—first test your tumor, then customize. Moderna's CEO has indicated the product could receive approval as early as 2027.

Third, more cancer cures are becoming possible. Currently validated in melanoma, Moderna and Merck are already advancing nine Phase II/III trials covering lung, bladder, and kidney cancers. The underlying mRNA technology is universal, with enormous potential in ovarian, cervical, and endometrial cancers. Admittedly, there's a long road from clinical success to large-scale commercialization, but the direction is clear: mRNA technology is moving from its COVID "one-hit wonder" to the vast frontier of cancer treatment. According to CITIC Construction Investment estimates, the global market could reach $21 billion (RMB 114.1 billion) by 2035, with China's market at RMB 10 billion scale.

Where are the investment opportunities? Aggregating brokerage views, companies positioned in personalized neoantigen mRNA routes are poised for value reassessment. From an industrial chain perspective, focus on three core themes:

First, innovative drug companies with closed-loop "AI algorithms + LNP delivery + clinical advancement" capabilities, such as Everest Medicines and CSPC Pharmaceutical Group. Second, high-certainty CXO "water sellers"—given the extreme customization of personalized vaccines, outsourcing penetration will rise significantly, benefiting WuXi AppTec and Asymchem Laboratories. Third, upstream core raw material suppliers with proprietary LNP delivery systems that break through "bottleneck" constraints, such as Jenkem Technology.

Chengtong Securities points out that the successful Phase III trial of therapeutic mRNA tumor vaccines opens new space for cancer treatment innovation, with the mRNA chain and innovative drug chain poised for sustained gains. The firm favors the mRNA industry chain, PD-1 combination therapy, and innovative drugs (CXO + innovative drugs) sectors.

Related ETFs: HK Connect Innovative Drug ETF Huabao (520880): Passively tracks the Hang Seng HK Connect Innovative Drug Select Index, with 100% allocation to innovative drug R&D companies and ~70% in R&D leaders; T+0 trading tool. Off-exchange feeder fund: 025221.

HK Connect Medical ETF Huabao (159137): Passively tracks the HK Connect Medical Thematic Index, heavily weighted in innovative drug chains—50% CXO plus 20% innovative drugs, with WuXi-related holdings exceeding 38%; T+0 trading tool. Off-exchange feeder fund: 026922.

Medical ETF Huabao (512170): Passively tracks the CSI Medical Index, covering 8 CXO leaders with combined weight over 30%. Flagship medical/pharma ETF: Q2 fund size of RMB 25.624 billion; average daily turnover of RMB 671 million year-to-date as of August 20. Off-exchange feeder fund: 012323.

Pharma ETF Huabao (562050): The only ETF tracking the pharmaceutical index in the market, with over 70% in A-share innovative drugs and over 20% in traditional Chinese medicine, balancing innovative drug growth with TCM dividends. Off-exchange feeder fund: 024986.

Data sourced from Shanghai/Shenzhen/Hong Kong exchanges, CSI Index, Hang Seng Index, and fund quarterly reports. Weight data as of 2026.8.20. Institutional views: CITIC Construction Investment industry event commentary dated 20260820; Chengtong Securities' 20260820 industry event commentary on Moderna/Merck's therapeutic mRNA tumor vaccine Phase III success.

Note: ETF funds do not charge sales service fees. When subscribing or redeeming fund shares, agents may charge commissions up to 0.5%, including fees from stock exchanges and registration institutions. Fund fee details are in each fund's legal documents.

Risk disclosure: Index constituents shown are for illustration only; individual stock descriptions do not constitute investment advice of any form, nor do they represent holdings or trading intentions of any fund under the manager. The manager rates Medical ETF and Pharma ETF Huabao and their feeder funds as R3-medium risk, suitable for balanced (C3) and above investors; HK Connect Innovative Drug ETF Huabao and its feeder fund, and HK Connect Medical ETF Huabao as R4-medium-high risk, suitable for aggressive (C4) and above investors. Any information in this article (including but not limited to stocks, comments, forecasts, charts, indicators, theories, or any form of expression) is for reference only; investors must bear responsibility for their own investment decisions. Additionally, any views, analyses, or forecasts herein do not constitute investment advice to readers, nor are they liable for direct or indirect losses from using this content. Performance of other funds managed by the manager does not guarantee fund performance; past performance does not indicate future results. Fund investment carries risk.